{"nctId":"NCT00661362","briefTitle":"Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes","startDateStruct":{"date":"2008-06"},"conditions":["Type 2 Diabetes"],"count":570,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Saxagliptin","Drug: Metformin"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Metformin"]}],"interventions":[{"name":"Saxagliptin","otherNames":["Onglyza"]},{"name":"Placebo","otherNames":[]},{"name":"Metformin","otherNames":["Glucophage"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosed with Type 2 diabetes\n* Treatment with metformin at a stable dose \\>1500 mg/day\n* HbA1c ≥ 7.0% and ≤10.0%\n\nExclusion Criteria:\n\n* Insulin therapy within one year of enrolment (with the exception of insulin therapy during a hospitalization or use in gestational diabetes)\n* Type 1 diabetes, history of ketoacidosis, or hyperosmolar non-ketonic koma","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c)","description":"Adjusted\\* mean change from baseline in HbA1c achieved with saxagliptin 5 mg + metformin versus placebo + metformin at week 24 (LOCF, Full Analysis set). HbA1c is a continuous measure, the change from baseline for each subject is calculated as the week 24 values minus the baseline value. \\*Adjusted for baseline HbA1c.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.90","spread":"0.049"},{"groupId":"OG001","value":"7.94","spread":"0.050"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.10","spread":"0.056"},{"groupId":"OG001","value":"7.55","spread":"0.062"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.78","spread":"0.051"},{"groupId":"OG001","value":"-0.37","spread":"0.050"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG) mmol/L","description":"Adjusted\\* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 5 mg + metformin versus placebo + metformin at week 24 (Last Observation Carried Out (LOCF), Full Analysis set). FPG is a continuous measure, the change from baseline for each subject is calculated as the week 24 values minus the baseline value. \\*Adjusted for baseline FPG.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.57","spread":"0.117"},{"groupId":"OG001","value":"8.87","spread":"0.137"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.61","spread":"0.117"},{"groupId":"OG001","value":"8.30","spread":"0.127"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.14","spread":"0.114"},{"groupId":"OG001","value":"-0.58","spread":"0.111"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG) mg/dL","description":"Adjusted\\* mean change from baseline in fasting plasma glucose (FPG) achieved with saxagliptin 5 mg + metformin versus placebo + metformin at week 24 (LOCF, Full Analysis set). FPG is a continuous measure, the change from baseline for each subject is calculated as the week 24 values minus the baseline value. \\*Adjusted for baseline FPG.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"154.54","spread":"2.103"},{"groupId":"OG001","value":"159.73","spread":"2.467"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"137.15","spread":"2.116"},{"groupId":"OG001","value":"149.54","spread":"2.286"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.52","spread":"2.051"},{"groupId":"OG001","value":"-10.42","spread":"2.004"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Area Under the Curve (AUC) From 0 to 180 Minutes for Postprandial Glucose (PPG) During a Mixed Meal Tolerance Test (MMTT) in a Subgroup","description":"Adjusted\\* mean change from baseline in PPG AUC achieved with saxagliptin 5 mg + metformin versus placebo + metformin at week 24 (LOCF, Full Analysis set). Trapezoidal method was used to compute AUC under the 3 hour PPG curve. The change from baseline for each subject is calculated as the week 24 value minus the baseline value. \\*Adjusted for baseline PPG AUC.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2355","spread":"45.6"},{"groupId":"OG001","value":"2427","spread":"51.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2058","spread":"44.4"},{"groupId":"OG001","value":"2249","spread":"46.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-315","spread":"38.6"},{"groupId":"OG001","value":"-160","spread":"39.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Area Under the Curve (AUC) From 0 to 180 Minutes for Postprandial Glucose (PPG) During a Mixed Meal Tolerance Test (MMTT) in a Subgroup","description":"Adjusted\\* mean change from baseline in PPG AUC achieved with saxagliptin 5 mg + metformin versus placebo+metformin at week 24 (LOCF, Full Analysis set). Trapezoidal method was used to compute AUC under the 3 hour PPG curve. The change from baseline for each subject is calculated as the week 24 value minus the baseline value. \\*Adjusted for baseline PPG AUC.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42423","spread":"821.9"},{"groupId":"OG001","value":"43719","spread":"927.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37071","spread":"799.4"},{"groupId":"OG001","value":"40521","spread":"845.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5673","spread":"695.9"},{"groupId":"OG001","value":"-2871","spread":"702.1"}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Achieving a Therapeutic Glycemic Response","description":"Proportion of participants achieving a therapeutic glycemic response, defined as having HbA1c \\< 7.0% for saxagliptin + metformin versus placebo + metformin at week 24","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.5","spread":null},{"groupId":"OG001","value":"30.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":283},"commonTop":["Upper Respiratory Tract Infection"]}}}